ALMS (Alumis) Inventories, Finished Goods: $0.00 Mil (As of Mar. 2026)


ALMS Alumis Inc ALMS
12 GF Score
Price $26.84
! 4 Warning Signs
View Full Analysis

What is Alumis Inventories, Finished Goods?

Alumis ALMS +1.61% 12 Inventories, Finished Goods is $0.00 Mil as of Mar. 2026. GuruFocus rates ALMS with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Alumis Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Alumis's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alumis Inventories, Finished Goods Chart

Alumis Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
0.00 0.00 0.00 0.00

Alumis Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ALMS
12GF Score
Alumis Inc ALMS
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alumis Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $0.00 Mil mean?
Alumis (ALMS) has a Inventories, Finished Goods of $0.00 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Alumis and its competitors.
Is Alumis' Inventories, Finished Goods too high?
Alumis' current Inventories, Finished Goods is $0.00 Mil. Overall, Alumis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alumis' Inventories, Finished Goods compare to ARQT and QURE?
Alumis' Inventories, Finished Goods of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Alumis and its competitors. Alumis's current Inventories, Finished Goods is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alumis stock overvalued right now?
Alumis (ALMS) has a current Inventories, Finished Goods of $0.00 Mil. The current Inventories, Finished Goods is $0.00 Mil. Alumis' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Alumis (ALMS), the current Inventories, Finished Goods is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alumis Business Description

Address 280 East Grand Avenue, South San Francisco, CA, USA, 94080
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
12GF Score

Get the complete analysis for ALMS

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.84
Price